******* The company released significant news this morning.
BROAD-SPECTRUM ANTIVIRAL NV-387 (NV-COV-2) IN PHASE 1A/1B CLINICAL TRIAL IS HIGHLY EFFECTIVE IN AN ANIMAL MODEL FOR MPOX AND SMALLPOX DRUG DEVELOPMENT ________________________________________________